Hims & Hers Health Inc (NYSE:HIMS) is one of the best performing stocks on the New York Stock Exchange (NYSE) today, up 4.5% to trade at $25.52. The telehealth name is buzzing after the Food and Drug Administration (FDA) scheduled a July meeting to consider several peptides to be added to a list compounding pharmacies are permitted to produce. The looser regulations could give Hims & Hers access to a popular market and help take some pressure of the company's GLP-1 prospects.
HIMS is heading for a fourth-straight win and gapped higher by 13.7% yesterday. The shares have nearly doubled off their Feb. 24 two-year low of $13.74, and today have cleared their descending 80-day moving average for the first time since October. However, the stock remains down 21% in 2026.
The equity is one of the most heavily-shorted names on the market, with 34.5% of its total available float sold short. Keep an eye on analyst upgrades too, with 12 of the 15 brokerages maintaining "hold" ratings.
At the International Securities Exchange (ISE), Cboe Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), HIMS' 10-day call/put volume ratio of 6.76 ranks in the top percentile of its annual range. Given the amount of short interest tied up in HIMS, it's possible some of these calls could be bearish bettors seeking an options hedge.
In just the first hour of trading, 131,000 calls have changed hands, volume that's six times the average intraday amount and seven times the number of puts traded. The weekly 4/24 28-strike call and May 30 calls are the most popular.
Good news for those premium buyers; the stock's Schaeffer's Volatility Scorecard (SVS) comes in at 87 out of 100. This indicates HIMS has consistently realized higher volatility than its options have priced in.
